%0 Journal Article
%T 系统性炎症指标在卵巢癌中的研究进展<br>Research Advances in Systemic Inflammatory Indicators in Ovarian Cancer
%A 张晓露
%A 刘芯瑜
%A 李红霞
%J Journal of Clinical Personalized Medicine
%P 835-842
%@ 2334-3443
%D 2025
%I Hans Publishing
%R 10.12677/jcpm.2025.42250
%X 系统性炎症指标作为一类简便易得的生物标志物&#65292;在卵巢癌的诊断、预后评估和治疗中展现出重要价值。本文综述了近年来淋巴细胞与单核细胞比值(LMR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、系统性炎症反应指数(SIRI)、纤维蛋白原与白蛋白比值(FAR)以及系统性免疫炎症指数(SII)在卵巢癌中的研究进展。这些指标不仅与卵巢癌的分期、化疗反应和预后密切相关&#65292;还可作为卵巢癌辅助诊断的重要参考。然而&#65292;这些指标在临床应用中仍面临临界值不统一、特异性有限、缺乏前瞻性研究验证等问题。未来需要探索这些指标的生物学机制&#65292;建立标准化评估体系&#65292;并研究其在卵巢癌个体化治疗中的应用价值&#65292;以提高卵巢癌患者的生存率和生活质量。<br>Systemic inflammatory indicators, as a category of readily accessible biomarkers, have demonstrated significant value in the diagnosis, prognostic evaluation, and treatment for ovarian cancer. This review summarizes recent advances in the study of lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), fibrinogen-to-albumin ratio (FAR), and systemic immune-inflammation index (SII) in ovarian cancer. These indicators are not only closely associated with tumor staging, chemotherapy response, and prognosis but also serve as valuable adjuncts for auxiliary diagnosis. However, challenges remain in their clinical application, including inconsistent cutoff values, limited specificity, and a paucity of validation through prospective studies. Future research should focus on elucidating the biological mechanisms underlying these indicators, establishing standardized evaluation protocols, and exploring their potential in personalized treatment strategies to improve survival rates and quality of life for ovarian cancer patients.
%K 卵巢癌&#65292
%K 炎症指标&#65292
%K 系统性免疫炎症指数<br>Ovarian Cancer
%K Inflammatory Indicators
%K Systemic Immune-Inflammation Index
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=111251